Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

CELL RESEARCH is a premier peer-reviewed journal dedicated to advancing the field of cell biology and molecular biology, published by SpringerNature. With an impressive impact factor and consistently ranking in the Q1 quartile for both cell biology and molecular biology, this journal serves as a pivotal resource for researchers, professionals, and students seeking to explore the latest discoveries and advancements in cellular mechanisms and their implications for health and disease. Since its inception in 1996, CELL RESEARCH has cultivated a distinguished reputation, currently boasting ranks in the top percentile of Scopus categories, reaffirming its influence and relevance to the scientific community. Although it is not an Open Access journal, its rigorous selection process ensures the publication of high-quality articles that contribute significantly to our understanding of life sciences. For those deeply engaged in the realms of biochemistry, genetics, and molecular biology, CELL RESEARCH is an essential conduit of innovative research and critical insights.

CELL PROLIFERATION, published by Wiley, is a leading open-access journal that has been at the forefront of research since its inception in 1968. With an impact factor that solidifies its position in the Q1 category of both Cell Biology and Medicine (Miscellaneous), this journal serves as a premier platform for disseminating groundbreaking studies in the field of cellular and molecular biology. The journal is renowned for its rigorous peer-review process and comprehensive coverage of topics related to cell growth, division, and differentiation, making it an invaluable resource for researchers, professionals, and students alike. With its notable Scopus ranking of #30 in Biochemistry, Genetics, and Molecular Biology: Cell Biology, and a robust open access model since 2019, CELL PROLIFERATION ensures that cutting-edge research is accessible to a global audience, fostering collaboration and innovation across the scientific community. Located in the United Kingdom, the journal remains committed to enhancing the understanding of cellular processes, thereby influencing developments in medicine and biotechnology.

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT, published by SAGE Publications Inc, is a leading open-access journal dedicated to the intersection of technology and oncology. Since its inception in 2002 and with an impactful transition to open access in 2018, it has garnered attention for its commitment to disseminating groundbreaking research that explores innovative methodologies and technologies in cancer diagnostics and therapeutics. With ISSN 1533-0346 and E-ISSN 1533-0338, the journal is highly relevant in the fields of Cancer Research (Q3), Medicine (Q2), and Oncology (Q3), as indicated by its 2023 category quartiles. Its Scopus rankings further highlight its position within the research community, standing at #186 out of 404 in Medicine and #141 out of 230 in Cancer Research. Through a carefully curated selection of articles, this journal aims to bridge the gap between technological advancement and clinical application, providing a vital resource for researchers, healthcare professionals, and students striving to improve cancer treatment outcomes.

FEBS Journal is a prestigious, peer-reviewed publication dedicated to advancing the field of biochemistry, cell biology, and molecular biology. Published by WILEY in the United Kingdom, this journal boasts an impressive impact factor and ranks in the top quartile (Q1) across multiple relevant categories, including Biochemistry, Cell Biology, and Molecular Biology, reflecting its significant contribution to scientific research. With an ISSN of 1742-464X and an E-ISSN of 1742-4658, the FEBS Journal publishes original research and comprehensive reviews that push the boundaries of knowledge and innovation in the biosciences. As a vital resource for researchers, professionals, and students alike, the journal offers Open Access options, ensuring that cutting-edge discoveries are accessible to a broad audience. With a publication history converging from 2005 to the present and a robust emphasis on high-quality scholarly work, the FEBS Journal remains an essential platform for the dissemination of significant findings and advancements in the life sciences.

ONCOGENE is a premier peer-reviewed journal published by SpringerNature, serving as a crucial platform for innovative research within the fields of Cancer Research, Genetics, and Molecular Biology. With an impressive Impact Factor and a distinguished Q1 ranking across major categories, ONCOGENE publishes cutting-edge studies aimed at unraveling the complexities of cancer biology and genetic mechanisms. The journal has been a vital resource for the academic community since its inception in 1987, and it continues to foster rigorous scientific discussions and collaborations. Researchers, professionals, and students can access a wealth of critical insights and advances in cancer genomics and therapeutic approaches, cementing ONCOGENE’s role as a leading voice in the landscape of biomedical research. For comprehensive academic research, ONCOGENE remains an indispensable source of knowledge with contributions that significantly impact the evolution of cancer research and treatment strategies.

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.